VRP.L Regulatory News (VRP)

9 May 2007 10:43

Verona Pharma PLC09 May 2007 Verona Pharma appoints WH Ireland as nominated adviser and broker Verona Pharma plc (AIM:VRP, the "Company"), the life sciences company developingnew drug treatments for allergic rhinitis (hay fever) and other chronicrespiratory and inflammatory diseases, is pleased to announce the appointment ofWH Ireland Limited as Nominated Adviser and Broker to the Company, withimmediate effect. For further information please contact: Verona Pharma plcProfessor Clive Page, Chairman 079 7150 4931www.veronapharma.com WH Ireland LimitedDavid Youngman 0161 832 2174 About Verona Pharma plc Verona Pharma plc is an AIM-listed drug discovery company that is focused onfinding new therapeutic drugs for the treatment of allergic rhinitis (hay fever)and other chronic respiratory diseases, such as asthma and chronic obstructivepulmonary disease (COPD), as well as chronic inflammatory diseases. The Companyis currently developing a long-acting bronchodilator/anti-inflammatory drug(belonging to a class of drugs known as mixed phosphodiesterase (PDE) 3/4inhibitors) that could be rapidly brought to clinical proof-of-concept for thetreatment of hay fever and be subsequently developed for the treatment ofasthma. Verona Pharma is also exploiting novel polysaccharides as potentialanti-inflammatory drugs for the treatment of respiratory allergies, asthma andother inflammatory diseases. For further information, visit the Verona Pharma website: www.veronapharma.com This information is provided by RNS The company news service from the London Stock Exchange